or Try an Advanced Search...

    Technical Analysis for PTN - Palatin Technologies, Inc.

    Grade Last Price % Change Price Change
    F 1.86 -4.62% -0.09
    PTN closed down 4.62 percent on Monday, July 1, 2024, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PTN trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    20 DMA Support Bullish -4.62%
    Crossed Above 50 DMA Bullish -4.62%
    MACD Bullish Signal Line Cross Bullish -4.62%
    Bollinger Band Squeeze Range Contraction -4.62%
    Earnings Movers Other -4.62%
    Up 3 Days in a Row Strength -4.62%
    Older End-of-Day Signals for PTN ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 5 hours ago
    20 DMA Support about 7 hours ago
    Fell Below 10 DMA about 7 hours ago
    10 DMA Support about 8 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PTN Chart by TradingView
    Basic chart:

    Profile

    Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity

    Is PTN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 21 Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
    Jun 21 Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
    Jun 20 Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
    Jun 13 Palatin Technologies commences Phase II study of obesity treatment
    Jun 12 Palatin starts Phase 2 obesity study of bremelanotide with Zepbound
    Jun 12 Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
    May 20 Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
    May 16 Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
    May 16 Q3 2024 Palatin Technologies Inc Earnings Call
    May 15 Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript
    See more PTN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.65
    52 Week Low 1.43
    Average Volume 146,482
    200-Day Moving Average 2.31
    50-Day Moving Average 1.95
    20-Day Moving Average 1.89
    10-Day Moving Average 1.88
    Average True Range 0.14
    RSI (14) 47.37
    ADX 14.32
    +DI 23.36
    -DI 14.55
    Chandelier Exit (Long, 3 ATRs) 1.70
    Chandelier Exit (Short, 3 ATRs) 2.17
    Upper Bollinger Bands 2.04
    Lower Bollinger Band 1.75
    Percent B (%b) 0.39
    BandWidth 15.37
    MACD Line -0.02
    MACD Signal Line -0.03
    MACD Histogram 0.0036
    Fundamentals Value
    Market Cap 30.01 Million
    Num Shares 16.1 Million
    EPS -2.15
    Price-to-Earnings (P/E) Ratio -0.87
    Price-to-Sales 11.87
    Price-to-Book 4.25
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.07
    Resistance 3 (R3) 2.09 2.03 2.04
    Resistance 2 (R2) 2.03 1.98 2.03 2.02
    Resistance 1 (R1) 1.95 1.95 1.92 1.93 2.01
    Pivot Point 1.89 1.89 1.88 1.89 1.89
    Support 1 (S1) 1.81 1.84 1.78 1.79 1.71
    Support 2 (S2) 1.75 1.81 1.75 1.70
    Support 3 (S3) 1.67 1.75 1.69
    Support 4 (S4) 1.65